FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...
There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback